a blood test for the early detection of pancreatic cancer in individuals at risk for developing familial or hereditary pancreatic ductal adenocarcinoma (PDAC)
Informing Patients about the IMMray PanCan-d test
Blood drawn at a location and time of your choosing.
Actionable results delivered 5 to 7 business days of specimen receipt.
What does early detection mean to you?
The IMMray PanCan-d test measures 9 biomarkers including CA19-9 to detect pancreatic ductal adenocarcinoma (PDAC) in a serum sample with 92% sensitivity and 99% specificity.
LUND, SWEDEN – Immunovia today announced results from the PanFAM-1 study. The PanFAM-1 study is a prospective, multi-center, investigational study, designed to assess the performance…
LUND, SWEDEN – The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory licensure, allowing physicians…
Pancreatic cancer is a low incidence disease with a high mortality rate. Most patients (80%) are diagnosed with late stage disease when the cancer has already metastasized and treatment options are limited. But, if detected early, 5-year survival rates jump from just 3% in late stage disease to 42%.
I IMMagine my children and grandchildren won’t have to worry about pancreatic cancer; I imagine peace of mind. **
Marilyn V., Meriden, CT
The average person’s risk for developing pancreatic cancer is very low, with a lifetime risk of just 1.6%. But, a strong family history of pancreatic cancer or certain germline genetic mutations, could make the risk higher.
Order a test
Download the IMMray PanCan-d test requisition.
Order a test, check on status of existing test orders, and access results.
View your invoice and process payments online.
* ”Early detection” signifying detection of stage I and II pancreatic ductal adenocarcinoma (PDAC).
** “Direct quote from person impacted by pancreatic cancer who was asked “What does early detection mean to you?”